Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. (Q35975738)

11 August 2017

Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. (English)

1 reference

11 August 2017

1 reference

Foster BJ

1

1 reference

11 August 2017

Newell DR

2

1 reference

11 August 2017

Carmichael J

3

1 reference

11 August 2017

Harris AL

4

1 reference

11 August 2017

Gumbrell LA

5

1 reference

11 August 2017

Jones M

6

1 reference

11 August 2017

Goodard PM

7

1 reference

11 August 2017

Calvert AH

8

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 February 1993

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

67

1 reference

11 August 2017

2

1 reference

11 August 2017

362-368

1 reference

Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

DTIC (NSC-45388) in malignant melanoma: a perspective

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Studies on the mechanism of action of DTIC (NSC-45388).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

In vivo estimation of size of experimental tumors.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Comparison of the antitumor activity of DTIC and 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on murine transplantable tumors and their hematological toxicity

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Walker carcinosarcoma 256 in study of anticancer agents. I. Method for simultaneous assessment of therapeutic value and toxicity

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Studies on the mechanism of action of the tumour inhibitory triazenes

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of alkyltriazenylimidazoles

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of 1-aryl-3-alkyltriazenes

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968184

Imidazoles. II. 5(or 4)-(Monosubstituted triazeno)imidazole-4(or 5)-carboxamides

24 September 2018

1 reference

12 December 2020

Mechanism of action and pharmacology studies with DTIC (NSC-45388)

1 reference

12 December 2020

Tumour inhibitory triazenes: Structural requirements for an active metabolite

1 reference

12 December 2020

Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives

1 reference

12 December 2020

Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice

1 reference

12 December 2020

Studies of the mode of action of antitumour triazenes and triazines-II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenes

1 reference

12 December 2020

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

1 reference

12 December 2020

Studies of the mode of action of antitumor triazenes and triazines. 6. 1-Aryl-3-(hydroxymethyl)-3-methyltriazenes: synthesis, chemistry, and antitumor properties

1 reference

12 December 2020

Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study

1 reference

12 December 2020

Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes

1 reference

12 December 2020

Development of plasma-cell neoplasms in BALB/c mice after intraperitoneal injection of paraffin-oil adjuvant, heart-killed Staphylococcus mixtures

1 reference

12 December 2020

Antitumor activity of triazenoimidazoles

1 reference

12 December 2020

Preparation and antitumor activity of derivatives of 1-phenyl-3,3-dimethyltriazene

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1993.66

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

PubMed publication ID

8431367

1 reference